8 December 2025

Oncoinvent ASA: Notification of trade – primary insider/close associate

2025-12-05 PDMR - Attachment subscription and allocation of UWC shares

8 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the “Company”) on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the fully underwritten rights issue of 260,000,000 new shares in the Company (the “Offer Shares”) raising gross proceeds of NOK 130 million (the “Rights Issue”). Further, reference is made to the stock exchange announcement published by the Company on 5 December 2025 regarding the resolution by the board of directors of the Company to issue 31,199,997 new shares in the Company, each with a nominal value of NOK 0.50, at a subscription price of NOK 0.50 per share (the “Underwriting Commission Shares”) to be delivered to the underwriters pursuant to the subscription and underwriting agreements dated 30 June 2025 as settlement of their entitlement to an underwriting fee under said agreements.

Please see the attached notifications of trade for information regarding the allocation and subscription of Underwriting Commission Shares by certain primary insiders and their close associates.

***

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act. 

 

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close